Publications
Research at the Leibniz Institute for Immunology focuses on the development of pioneering immune-cell therapies targeting cancer, autoimmune diseases, and chronic inflammation. While developments in this field are highly relevant within the medical community, they are also of great interest to the wider general public. The LIT has a comprehensive archive of international articles, publications, lectures, and online resources aimed at a variety of audiences. So, whoever you are, if you do not find what you are looking for, please do not hesitate to contact us.
Doering J, Perl M, Weber D, Banas B, Schulz C, Hamer OW, Angstwurm K, Holler E, Herr W, Edinger M, Wolff D, Fante MA. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis. Transplant Cell Ther. 2023 Dec. 29:772 e771-772 e710. doi:10.1016/j.jtct.2023.09.016. PMID: 37777112
Larson-Casey JL, Saleem K, Surolia R, Pandey J, Mack M, Antony VB, Bodduluri S, Bhatt SP, Duncan SR, Carter AB. Myeloid Heterogeneity Mediates Acute Exacerbations of Pulmonary Fibrosis. J Immunol. 2023 Dec 1. 211:1714-1724. doi:10.4049/jimmunol.2300053. PMID: 37782053
Guinan EC, Contreras-Ruiz L, Crisalli K, Rickert C, Rosales I, Makar R, Colvin R, Geissler EK, Sawitzki B, Harden P, Tang Q, Blancho G, Turka LA, Markmann JF. Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial. Am J Transplant. 2023 Dec. 23:1872-1881. doi:10.1016/j.ajt.2023.06.012. PMID: 37422112
Blanco-Carmona E, Narayanan A, Hernandez I, Nieto JC, Elosua-Bayes M, Sun X, Schmidt C, Pamir N, Ozduman K, Herold-Mende C, Pagani F, Cominelli M, Taranda J, Wick W, von Deimling A, Poliani PL, Rehli M, Schlesner M, Heyn H, Turcan S. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas. Cell Rep Med. 2023 Nov 21. 4:101249. doi:10.1016/j.xcrm.2023.101249. PMID: 37883975
Kleber J, Yang Zhou J, Weber F, Bitterer F, Hauer P, Kupke P, Kronenberg K, Geissler EK, Schlitt HJ, Hornung M, Hutchinson JA, Werner JM. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy. Cancer Immunol Immunother. 2023 Nov. 72:3867-3873. doi:10.1007/s00262-023-03515-2. PMID: 37580610
Joachim L, Gottert S, Sax A, Steiger K, Neuhaus K, Heinrich P, Fan K, Orberg ET, Kleigrewe K, Ruland J, Bassermann F, Herr W, Posch C, Heidegger S, Poeck H. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors. EBioMedicine. 2023 Nov. 97:104834. doi:10.1016/j.ebiom.2023.104834. PMID: 37865045
Gavriilaki E, Sakellari I, Labopin M, Bornhauser M, Hamladji RM, Casper J, Edinger M, Zak P, Yakoub-Agha I, Ciceri F, Schroeder T, Zuckerman T, Kobbe G, Yeshurun M, Narni F, Finke J, Diez-Martin JL, Berceanu A, Hilgendorf I, Verbeek M, Olivieri A, Savani B, Spyridonidis A, Nagler A, Mohty M. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant. 2023 Oct. 58:1084-1088. doi:10.1038/s41409-023-02028-x. PMID: 37420011
Altvater B, Kailayangiri S, Spurny C, Flugge M, Meltzer J, Greune L, Urban K, Schwoppe C, Brand C, Schliemann C, Hintelmann H, Harrach S, Hartmann W, Abken H, Kuehle J, Schambach A, Gorlich D, Berdel WE, Rossig C. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process. Cancer Gene Ther. 2023 Oct. 30:1355-1368. doi:10.1038/s41417-023-00642-x. PMID: 37391502
Bittner S, Hehlgans T, Feuerer M. Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond. Trends Immunol. 2023 Jun;44(6):468-483. doi: 10.1016/j.it.2023.04.005. Epub 2023 Apr 25. PMID: 37100644 Free article. Review.
Ciulean IS, Fischer J, Quaiser A, Bach C, Abken H, Tretbar US, Fricke S, Koehl U, Schmiedel D, Grunwald T. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol. 2023 14:1290488. doi:10.3389/fimmu.2023.1290488. PMID: 38022580